Mark Napoli, MD
Interventional Cardiology · Monroe, LANPI 1811984537
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.5% of the total across 704 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,691 and has fallen 53.7% since, to $1,245 in 2025.
Across 704 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Amgen$1K
- Abbott$952
- Johnson & Johnson$879
- plus $6K from 33 others
Across 631 payments — averaging $3696.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$670K
- Eli Lilly$654K
- Novartis$365K
- Merck$151K
- Boehringer Ingelheim International GmbH$133K
- Janssen Research & Development, LLC$123K
- plus $236K from 6 others
What the payments were for
- Travel & lodging$1,1529%
- Food & beverage$12,36091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 16 | $1,543 |
| Novartis | 109 | $1,384 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 94 | $1,307 |
| Amgen | 66 | $1,146 |
| Abbott | 10 | $952 |
| Johnson & Johnson | 67 | $879 |
| Sanofi-aventis U.S. LLC | 42 | $690 |
| Actelion Pharmaceuticals US, Inc. | 43 | $674 |
| Kowa Pharmaceuticals America, Inc. | 28 | $528 |
| Pfizer | 38 | $517 |
| Medtronic(2 entities) | 12 | $485 |
| Bayer | 23 | $436 |
| Boehringer Ingelheim | 26 | $412 |
| Merck | 17 | $316 |
| Amarin Pharma, Inc. | 18 | $288 |
| Esperion Therapeutics, Inc. | 13 | $285 |
| E.r. Squibb & Sons, L.L.C. | 17 | $246 |
| AstraZeneca | 14 | $187 |
| Boston Scientific | 3 | $162 |
| Abiomed | 3 | $162 |
| Idorsia Pharmaceuticals US Inc | 1 | $117 |
| Lexicon Pharmaceuticals, Inc. | 6 | $107 |
| Regeneron Healthcare Solutions, Inc. | 6 | $106 |
| Irhythm Technologies, Inc. | 5 | $91 |
| Scpharmaceuticals Inc. | 5 | $84 |
| Novo Nordisk | 4 | $66 |
| Itamar Medical Inc | 2 | $48 |
| Inari Medical, Inc. | 2 | $42 |
| Cvrx, Inc. | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Penumbra, Inc. | 2 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $24 |
| Philips North America LLC | 1 | $24 |
| Bridgebio Pharma, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Gilead | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$334
- Confirm Rx$228
- Xience Sierra Coronary Stent System$189
- AVEIR$125
- NEXLIZET$125
- NEXLETOL$125
- WATCHMAN Access System$124
- QUVIVIQ$117
- LifeVest$110
- Impella$105
- JOT DX$103
How this compares
$13,512 in reported general payments places this provider in the 60th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 139 | $108,210 |
| EntrestoSacubitril/Valsartan | 63 | $46,604 |
| Repatha SureclickEvolocumab | 48 | $37,848 |
| XareltoRivaroxaban | 40 | $24,783 |
| JardianceEmpagliflozin | 29 | $19,319 |
| NexlizetBempedoic Acid/Ezetimibe | 23 | $9,078 |
| Rosuvastatin Calcium | 296 | $4,851 |
| Ezetimibe | 144 | $4,028 |
| Amiodarone Hcl | 107 | $3,802 |
| Atorvastatin Calcium | 223 | $3,300 |
| Losartan Potassium | 199 | $2,563 |
| Ranolazine ErRanolazine | 37 | $2,177 |
| SotalolSotalol Hcl | 111 | $1,371 |
| Flecainide Acetate | 19 | $1,352 |
| ClopidogrelClopidogrel Bisulfate | 109 | $1,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $517 | $108,210139 claims |
| NovartisEntresto | $1,384 | $46,60463 claims |
| Johnson & JohnsonXarelto | $879 | $24,78340 claims |
| Boehringer IngelheimJardiance | $412 | $19,31929 claims |
| Esperion Therapeutics, Inc.Nexlizet | $285 | $9,07823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Monroe
- Nauman KhalidMonroe$31K
- Gregory SampognaroMonroe$18K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
- Louis SalvaggioLafayette$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.